Fig. 1 · Structure

Documents & Downloads

BV-6

Cat. No. A14231 CAS 1001600-56-1

dual cIAP and XIAP inhibitor

BV-6 is a SMAC mimetic, dual cIAP and XIAP inhibitor.

In Stock

Publications for BV-6

2 publications citing this product

  1. Ximena Hildebrandt, .et al. , Sci Adv, 2025, Sep 17;11(38):eadw2539 PMID: 40961178
  2. Aneri Shah, .et al. , Cancers (Basel), 2020, Aug 5;12(8):E2188 PMID: 32764479

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

BV6 antagonizes IAP function through complementary effects. In a purified assay, it partially restored caspase-3 and caspase-7 activity suppressed by XIAP BIR2–BIR3, whereas the enantiomer BVE6 did not show comparable activity. In cancer cells, BV6 decreased cIAP1 and/or cIAP2 protein abundance and increased NIK, with cell-dependent p100-to-p52 processing. The cellular blots establish protein and signaling responses; they do not measure binding affinity. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

BV-6 Research Summary

This section summarizes 4 in vitro studies and 3 in vivo studies of BV-6 from 4 published references. In vitro models include purified recombinant caspase-3 or caspase-7 with XIAP BIR2–BIR3; KMS12.BM, MMI.s, RPMI, KMS.11, HT29 and HT1080 human cancer cells.

BV-6 In Vitro Studies

Single-agent responses varied across cancer cell lines. At 10 μM BV6, MTT viability decreased significantly in several lines, while Amo-1, KMS.11 and HeLa showed no significant decrease at 48 h. MTT viability is not a direct apoptosis measurement. In a separate human SGBS adipocyte model, HOIP loss increased susceptibility to TNF plus 500 nM BV6, with protection by a pan-caspase inhibitor. The adipocyte experiment used Selleck BV6; the paper’s separate Adooq A14231 methods entry does not establish Adooq use for that result. [2,3]

Relief of XIAP-mediated caspase inhibition

Biochemical assay · Purified recombinant caspase-3 or caspase-7 (300 pM) with XIAP BIR2–BIR3 (10 nM) [1]

BV6 restored caspase activity in a concentration-dependent but partial manner; BVE6, described as the nonbinding enantiomer, did not show comparable restoration. This is an activity-rescue assay, not a BV6 binding-affinity measurement.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Caspase-3 and caspase-7 activity after XIAP inhibitionQualitative result Concentration-dependent partial restoration by BV6; little restoration by BVE6.[1]

Literature-Reported Treatment Conditions

Treatment concentration
BV6 or BVE6: 0.02, 0.07, 0.20, 0.61, 1.83, 5.49, 16.5, 49.4, 148 and 444 μM, as printed in Figure 5A–B.
Exposure duration
1 h preincubation at room temperature; kinetic read for 30 min at 37°C after substrate addition.
Method
Fluorogenic ac-DEVD-AFC cleavage (25 μM substrate); enzyme-only control assigned 100% and enzyme plus XIAP without antagonist assigned 0%.
Vehicle
DMSO; matched replacement when compounds were absent.
Methods and source locations

Compound reported in the paper: BV-6; Compound label in the paper: BV6

Evidence concerns the named BV6 reagent in the reported model; it does not validate an Adooq lot or establish clinical efficacy.

Figure 5A–B; Experimental Procedures—Caspase Activity Assay; Results—XIAP discussion preceding Figure 5

Caspase-3 and caspase-7 activity after XIAP inhibition: Fluorogenic enzyme assay; no exact bar heights extracted. — Figure 5A–B; Caspase Activity Assay

cIAP protein loss and NIK accumulation in cancer cells

Cell-based study · KMS12.BM, MMI.s, RPMI, KMS.11, HT29 and HT1080 human cancer cells [2]

BV6 decreased cIAP1 and/or cIAP2 abundance and increased NIK. Increased p100 processing to p52 was reported principally in KMS12.BM, HT29 and HT1080. The patterns varied across cells; these blots do not directly measure BV6 binding or prove proteasomal dependence.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cIAP1/cIAP2, NIK and p100/p52 protein patternsQualitative result cIAP protein loss and NIK accumulation; cell-dependent p100-to-p52 processing.[2]

Literature-Reported Treatment Conditions

Treatment concentration
0, 0.016, 0.08, 0.4, 2 and 10 μM BV6.
Exposure duration
8 h
Method
Western blotting with tubulin loading control.
Reported limits
Vehicle for the Figure 1 zero-dose lanes and biological replicate count are not specified in its caption; no densitometric effect size reported there.
Methods and source locations

Compound reported in the paper: BV-6; Compound label in the paper: BV6

Evidence concerns the named BV6 reagent in the reported model; it does not validate an Adooq lot or establish clinical efficacy.

Figure 1 image/caption; Results—BV6 induces IAPs degradation and NIK accumulation; Chemicals and Western blotting methods

cIAP1/cIAP2, NIK and p100/p52 protein patterns: Western blot; qualitative interpretation only. — Figure 1; corresponding Results paragraph

Cell-dependent single-agent viability response

Cell-based study · Eleven human cancer cell lines: KMS12.BM, L363, MMI.s, OPM2, RPMI, Amo-1, KMS.11, HT29, HT1080, HeLa and Jurkat [2]

At 10 μM, statistically significant MTT viability decreases were reported at 24 h in L363, MMI.s, HT1080 and Jurkat, and at 48 h in all tested lines except Amo-1, KMS.11 and HeLa. The MTT endpoint alone does not identify apoptosis.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MTT viability at 24 hQualitative result Significant decrease: L363, MMI.s, HT1080 and Jurkat.[2]
MTT viability at 48 hQualitative result Significant decrease in tested lines except Amo-1, KMS.11 and HeLa.[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM BV6
Exposure duration
24 or 48 h
Method
MTT viability assay; Student’s t-test in shared Statistical analysis.
Vehicle
PBS:methanol (1:1), reported BV6 vehicle control.
Methods and source locations

Compound reported in the paper: BV-6; Compound label in the paper: BV6

Evidence concerns the named BV6 reagent in the reported model; it does not validate an Adooq lot or establish clinical efficacy.

Figure 2 image/caption; Results—BV6 induces cell death in different human cell lines; Cell death assay and Statistical analysis

MTT viability at 24 h: MTT, triplicate treatments. — Figure 2; Results—BV6 induces cell death in different human cell lines

MTT viability at 48 h: MTT; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 defined in shared methods; no per-bar values inferred. — Figure 2; corresponding Results paragraph

HOIP deficiency increases adipocyte susceptibility to TNF plus BV6

Cell-based study · Differentiated human SGBS adipocytes: empty-vector control versus HOIP-knockout clone 1.1.1 [3]

HOIP-deficient adipocytes were more susceptible to TNF plus BV6 than empty-vector cells. In the inhibitor comparison, zVAD prevented death without an additional benefit from 7-O-Cl-Nec-1, consistent with caspase-dependent death in this context. This does not demonstrate a BV6 effect on obesity in animals.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Viability under TNF plus BV6Qualitative result Greater susceptibility in HOIP-KO than EV cells.[3]
Effect of cell-death inhibitors on TNF/BV6 viabilityQualitative result zVAD rescue, without additional protection from RIPK1 inhibition.[3]

Literature-Reported Treatment Conditions

Treatment concentration
500 nM BV6; increasing TNF in Figure 5I; TNF 0.1 ng/mL in Figure 5J.
Exposure duration
24 h
Method
CellTiter-Glo ATP-based viability assay.
Vehicle
DMSO control; viability in Figure 5J is expressed relative to DMSO.
Co-treatment
TNF; Figure 5J additionally compares zVAD-fmk (20 μM), 7-O-Cl-Nec-1 (10 μM), or both.
Methods and source locations

Compound reported in the paper: BV-6; Compound label in the paper: BV6

Evidence concerns the named BV6 reagent in the reported model; it does not validate an Adooq lot or establish clinical efficacy.

Figure 5I–J image/caption; human adipocyte Results; Methods—SGBS cell culture and Human and mouse pre- and adipocytes

Viability under TNF plus BV6: CellTiter-Glo; n = 3; means ± SD. — Figure 5I image/caption; associated Results

Effect of cell-death inhibitors on TNF/BV6 viability: CellTiter-Glo; n = 5; means ± SD; qualitative result, no curve-derived percentages. — Figure 5J image/caption; associated Results; human adipocyte viability methods

BV-6 In Vivo Studies

In subcutaneous MDA-MB-231-X1.1 xenografts, BV6 inhibited tumor growth, and combination with a DR5 agonist antibody produced stronger inhibition than either single agent. Animal outcomes were context dependent: in a separate BALB/c skeletal 4T1-Fluc model, BV6 increased skeletal tumor burden and osteolysis. Zoledronic acid opposed the increase in burden and bone loss but did not reduce the mean number of skeletal tumor sites. These findings do not establish a uniform antitumor effect across anatomical sites. [1,4]

BV6 also caused bone loss without tumor challenge: two or four weekly 10 mg/kg doses reduced trabecular bone volume in BALB/c mice. Increased bone-formation indices were insufficient to offset the accompanying increase in resorption. This limits extrapolation from cancer-cell cytotoxicity to net benefit in bone. [4]

BV6 and DR5 agonist inhibit breast-tumor xenograft growth

Animal study · Female C.B-17 SCID.bg mice, 9–19 weeks old, bearing subcutaneous MDA-MB-231-X1.1 breast-carcinoma xenografts [1]

Mice were randomized when tumors were established (100–200 mm³; approximately 150 mm³ mean in caption), with five animals per group. BV6 and DR5 agonist antibody each inhibited tumor growth; the combination produced substantially stronger growth inhibition. No exact tumor-volume values are inferred from the graph.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor growthQualitative result Each single agent inhibited growth; combination showed stronger inhibition.[1]

Conditions shared by the study groups

Route
Intravenous
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
VehicleVehicle comparator; n = 5.Progressive tumor growth.[1]
BV6
10 mg/kg
Vehicle; n = 5 per group.Tumor-growth inhibition versus vehicle.[1]
DR5 agonist antibody
3 mg/kg PRO95780
Vehicle; n = 5 per group.Tumor-growth inhibition versus vehicle.[1]
BV6 plus DR5 agonist antibody
BV6 10 mg/kg plus PRO95780 3 mg/kg.
Vehicle and both single-agent groups; n = 5 per group.Greater growth inhibition than either single agent; described as almost complete growth inhibition, not tumor eradication.[1]
Vehicle
Frequency: Matched schedules of the corresponding agents.
Treatment course: Growth followed through day 25 in Figure 3B.
Vehicle: BV6 vehicle: 15% hydroxypropyl-β-cyclodextrin and 20 mM succinic acid; antibody vehicle: 20 mM histidine, 240 mM trehalose, 0.02% polysorbate 20, pH 6.
BV6
Frequency: Every 4 days, six treatments, starting day 1.
Treatment course: q4d × 6
Vehicle: 15% hydroxypropyl-β-cyclodextrin and 20 mM succinic acid.
DR5 agonist antibody
Frequency: Once on day 0.
Treatment course: Single dose.
Vehicle: 20 mM histidine, 240 mM trehalose, 0.02% polysorbate 20, pH 6.
BV6 plus DR5 agonist antibody
Frequency: BV6 every 4 days × 6 from day 1; antibody once on day 0.
Treatment course: Schedules as specified above.
Vehicle: Corresponding agent vehicles.
Methods and source locations

Compound reported in the paper: BV-6; Compound label in the paper: BV6

Evidence concerns the named BV6 reagent in the reported model; it does not validate an Adooq lot or establish clinical efficacy.

Figure 3B image/caption; Tumor Xenograft Study; Results paragraph introducing Figure 3

Tumor growth: Caliper volumes, v = 0.5 × a × b², measured twice weekly; n = 5 per group. Figure 3B error-bar definition not specified in its caption. — Figure 3B; Tumor Xenograft Study; associated Results

Vehicle · Figure 3B image/caption; Tumor Xenograft Study; Results paragraph introducing Figure 3

BV6 · Figure 3B image/caption; Tumor Xenograft Study; Results paragraph introducing Figure 3

DR5 agonist antibody · Figure 3B image/caption; Tumor Xenograft Study; Results paragraph introducing Figure 3

BV6 plus DR5 agonist antibody · Figure 3B image/caption; Tumor Xenograft Study; Results paragraph introducing Figure 3

BV6 causes trabecular bone loss with increased bone turnover

Animal study · Six-week-old BALB/c mice; distal femur and serum analysis after BV6 or vehicle [4]

Two or four weekly BV6 doses reduced trabecular bone volume relative to vehicle. After four doses, serum CTX and osteocalcin and osteoclast-covered surface were increased. Increased bone-formation indices did not offset resorption.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Trabecular bone volume fraction (BV/TV)Relative decrease 9% reduction after two weekly doses; 35% reduction after four weekly doses, relative to vehicle.[4]
Bone resorption and formation markersQualitative result Increased serum CTX, osteocalcin, osteoclast surface, mineral apposition and bone formation rate.[4]

Conditions shared by the study groups

Route
Intraperitoneal
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehiclen = 6/group for two doses; n = 7/group for four doses in bone-volume analysis.Reference bone mass and turnover.[4]
BV6
10 mg/kg
Matched vehicle; n = 6/group for two doses; n = 7/group for four doses in bone-volume analysis.Trabecular BV/TV decreased by 9% and 35% after two and four doses, respectively, versus matched vehicle.[4]
Vehicle
Frequency: Weekly, matched to two- or four-dose groups.
Treatment course: Femur analyzed 7 days after final dose.
Reported limits: Vehicle composition and group sex not specified in selected main-text methods/caption.
BV6
Frequency: Weekly; two or four doses.
Treatment course: Distal femur analyzed 7 days after final dose.
Reported limits: Vehicle composition and group sex not specified in selected main-text methods/caption.
Methods and source locations

Compound reported in the paper: BV-6; Compound label in the paper: BV6

Evidence concerns the named BV6 reagent in the reported model; it does not validate an Adooq lot or establish clinical efficacy.

Figure 2A–K image/caption; Results—IAP antagonists cause high bone turnover osteoporosis; Reagents and mice; Histomorphometric analysis

Trabecular bone volume fraction (BV/TV): μCT; n = 6/group and n = 7/group respectively; figure data mean ± s.d. — Figure 2A; first paragraph under IAP antagonists cause high bone turnover osteoporosis

Bone resorption and formation markers: ELISA and histomorphometry. CTX/osteocalcin: vehicle n = 5, BV6 n = 6; osteoclast surface n = 7/group; formation indices n = 6/group. Means ± s.d.; no graph-derived values. — Figure 2E–K and corresponding Results

Vehicle · Figure 2A–K image/caption; Results—IAP antagonists cause high bone turnover osteoporosis; Reagents and mice; Histomorphometric analysis

BV6 · Figure 2A–K image/caption; Results—IAP antagonists cause high bone turnover osteoporosis; Reagents and mice; Histomorphometric analysis

BV6 enhances skeletal tumor growth; zoledronic acid opposes the effect

Animal study · BALB/c mice with intracardiac 4T1-Fluc breast-cancer-cell challenge; skeletal bioluminescence and femoral μCT [4]

BV6 increased skeletal tumor burden, the number of skeletal tumor sites and osteolysis. Zoledronic acid reduced BV6-enhanced skeletal tumor burden and reversed bone loss, but did not change the average number of metastatic sites. Results distinguish tumor burden from metastatic-site count.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Combined hind-leg and mandibular tumor bioluminescenceQualitative result BV6 approximately doubled skeletal tumor burden versus vehicle at day 13; zoledronic acid opposed this increase.[4]
Number of distinct skeletal tumor sitesQualitative result Increased with BV6; zoledronic acid did not alter mean site count in either background.[4]
Femoral trabecular BV/TVRelative decrease 78% decrease with BV6 versus vehicle; reversed by zoledronic acid cotreatment.[4]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Weekly for four weeks.
Treatment course
Tumor challenge after third dose; skeletal imaging on days 7, 10 and 13 after challenge.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
VehicleFour-arm comparison; Vehicle n = 15.Reference skeletal tumor burden and bone mass.[4]
Zoledronic acid
40 μg/kg zoledronic acid
Four-arm comparison; Zoledronic acid n = 12.Reduced skeletal tumor burden and increased bone mass; no change in mean number of metastatic sites.[4]
BV6
10 mg/kg BV6
Four-arm comparison; BV6 n = 9.Higher skeletal tumor burden and more skeletal tumor sites; marked trabecular bone loss.[4]
BV6 plus zoledronic acid
10 mg/kg BV6 plus 40 μg/kg zoledronic acid
Four-arm comparison; BV6 plus zoledronic acid n = 9.Skeletal tumor burden returned to approximately vehicle level; bone loss reversed; metastatic-site count not reduced.[4]
Vehicle
Reported limits: Vehicle composition and animal sex not specified for Figure 6 in retained main-text methods/caption.
Zoledronic acid
Reported limits: Vehicle composition and animal sex not specified for Figure 6 in retained main-text methods/caption.
BV6
Reported limits: Vehicle composition and animal sex not specified for Figure 6 in retained main-text methods/caption.
BV6 plus zoledronic acid
Reported limits: Vehicle composition and animal sex not specified for Figure 6 in retained main-text methods/caption.
Methods and source locations

Compound reported in the paper: BV-6; Compound label in the paper: BV6

Evidence concerns the named BV6 reagent in the reported model; it does not validate an Adooq lot or establish clinical efficacy.

Figure 6A–F image/caption; Results—BV6 preferentially promotes bone metastasis, which is effectively blocked by bisphosphonates; Tumor inoculation and bioluminescent imaging analysis and Discussion

Combined hind-leg and mandibular tumor bioluminescence: Bioluminescence summed from hind legs and mandibles; means ± s.d.; numerical fold statement from prose. — Figure 6B–C; Results paragraph introducing Figure 6

Number of distinct skeletal tumor sites: Discrete sites in hind legs/mandible counted; this is not the same endpoint as total burden. — Figure 6D; associated Results

Femoral trabecular BV/TV: μCT; percentage taken from Results, not estimated from plot. — Figure 6E–F; associated Results

Vehicle · Figure 6A–F image/caption; Results—BV6 preferentially promotes bone metastasis, which is effectively blocked by bisphosphonates; Tumor inoculation and bioluminescent imaging analysis and Discussion

Zoledronic acid · Figure 6A–F image/caption; Results—BV6 preferentially promotes bone metastasis, which is effectively blocked by bisphosphonates; Tumor inoculation and bioluminescent imaging analysis and Discussion

BV6 · Figure 6A–F image/caption; Results—BV6 preferentially promotes bone metastasis, which is effectively blocked by bisphosphonates; Tumor inoculation and bioluminescent imaging analysis and Discussion

BV6 plus zoledronic acid · Figure 6A–F image/caption; Results—BV6 preferentially promotes bone metastasis, which is effectively blocked by bisphosphonates; Tumor inoculation and bioluminescent imaging analysis and Discussion

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1001600-56-1
Applications dual cIAP and XIAP inhibitor
Formula C70H96N10O8
Molecular Weight 1205.57
SMILES
C[C@@H](C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)NCCCCCCNC(=O)[C@H](C(C5=CC=CC=C5)C6=CC=CC=C6)NC(=O)[C@@H]7CCCN7C(=O)[C@H](C8CCCCC8)NC(=O)[C@H](C)NC)NC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 96 mg/mL (79.62 mM)
Water 24 mg/mL (19.9 mM)
Ethanol Warmed: 96 mg/mL (79.62 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

BV-6 Research References

  1. [1] Varfolomeev E, Alicke B, Elliott JM, et al. X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists The Journal of biological chemistry (2009). PMID: 19854829 DOI: 10.1074/jbc.m109.040139 Source material
  2. [2] El-Mesery M, Shaker ME, Elgaml A. The SMAC mimetic BV6 induces cell death and sensitizes different cell lines to TNF-α and TRAIL-induced apoptosis Experimental biology and medicine (Maywood, N.J.) (2016). PMID: 27465142 DOI: 10.1177/1535370216661779 Source material
  3. [3] Hildebrandt X, Veli Ö, Hyoubi A, et al. Linear ubiquitination prevents lipodystrophy and obesity-associated metabolic syndrome Science advances (2025). PMID: 40961178 DOI: 10.1126/sciadv.adw2539 Source material
  4. [4] Yang C, Davis JL, Zeng R, et al. Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation Cancer discovery (2013). PMID: 23269702 DOI: 10.1158/2159-8290.cd-12-0271 Source material

Publications

2 publications citing this product

  1. Ximena Hildebrandt, .et al. , Sci Adv, 2025, Sep 17;11(38):eadw2539 PMID: 40961178
  2. Aneri Shah, .et al. , Cancers (Basel), 2020, Aug 5;12(8):E2188 PMID: 32764479

Added to your cart

View Cart Checkout
Loading...